# Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients

> **NCT05769582** · PHASE2,PHASE3 · COMPLETED · sponsor: **Memo Therapeutics AG** · enrollment: 95 (actual)

## Conditions studied

- BK Viremia; BKV DNAemia

## Interventions

- **BIOLOGICAL:** Anti-BK polyomavirus (AntiBKV)

## Key facts

- **NCT ID:** NCT05769582
- **Lead sponsor:** Memo Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-10
- **Primary completion:** 2025-03-19
- **Final completion:** 2025-07-15
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2025-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05769582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05769582, "Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05769582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*